The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
YapTA, VidalL, AdamJ, Phase 1 trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010;28(25): 3965–3972.
2.
StopferP, MarzinK, NarjesH, Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol. 2012;69(4):1051–1061.
3.
YangJCH, ShihJY, SuWC, Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutation (LUX-Lung 2): A phase 2 trial. Lancet Oncol. 2012;13(5):539–548.
4.
MillerVA, HirshV, CadranelJ, Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of eroltinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial. Lancet Oncol. 2012;13(5):528–538.
5.
KatakamiN, AtagiS, GotoK, LUX-Lung 4: A phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013;31(27):3335–3341.
6.
GordonMS, MendelsonDS, GrossM, A phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013;31(2):409–416.
7.
SequistLV, YangJC, YamamotoN, Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–3334.
SallesG, MorschhauserF, LamyT, Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012;119(22):5126–5132.
10.
SehnL, AssoulineS, StewartD, A phase I study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood. 2012;119(22):5118–5125.
11.
OguraM, TobinaiK, HatakeK, Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2013;104(1):105–110.
MorschhauserFA, CartronG, ThieblemontC, Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle cell lymphoma: Results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2912–2919.
14.
SallesGA, MorschhauserF, Solal-CelignyP, Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: Results from the phase II GAUGUiN study. J Clin Oncol. 2013;31(23): 2920–2926.
15.
GoedeV, FischerK, BuschR, Head-to-head comparison of obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (co-morbidities): Final stage 2 results of the CLL11 trial. https://ash.confex.com/ash/2013/webprogram/Paper60276.html.
